Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/455)
  • Patent number: 10301265
    Abstract: The invention provides potent quinolinol-based BoNT/A small-molecule inhibitors of botulinum neurotoxins, in particular of Clostridium botulinum serotype A neurotoxins. The invention also provides methods of using these small-molecule inhibitors to inhibit infections by Clostridium botulinum, as well as, methods of preventing infections by Clostridium botulinum through materials that may be ingested.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: May 28, 2019
    Inventors: Virginia I. Roxas-Duncan, Leonard A. Smith, Nizamettin Gul, John H. Cardellina, II, Rebecca C. Vieira, Susan M. Ensel, David C. H. Yang, Istvan J. Enyedy, Sivanesan Dakshanamurthy, Salimuddin Shah
  • Patent number: 10251902
    Abstract: The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-C-glucose derivatives or galenical extracts containing flavone-6-C-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: April 9, 2019
    Assignee: DAE HWA PHARMA CO., LTD.
    Inventors: Jong Hoon Ryu, Jae Hoon Cheong, Chan Young Shin, Dae Sik Jang, Hyung Eun Lee, Hyun Ji Kim, Byeol Ryu, In Ho Jung, Yeong Woo Jo
  • Patent number: 10195176
    Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 5, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Hui-Chun Wang, Yang-Chang Wu, Fang-Rong Chang, Chin-Chung Wu
  • Patent number: 9962366
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 8, 2018
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 9918962
    Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 20, 2018
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Hui-Chun Wang, Yang-Chang Wu, Fang-Rong Chang, Chin-Chung Wu
  • Patent number: 9901596
    Abstract: A method of using dibenzo-alpha-pyrones (DBPs) is provided wherein a subject is administered one or more of the aforementioned resulting in decreased body weight gain. In an embodiment, a 3-OH-DBP, 3,8-(OH)2-DBP, or a combination thereof is administered to an individual to control body weight gain.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: February 27, 2018
    Assignee: Natreon, Inc.
    Inventor: Chandan K. Sen
  • Patent number: 9809615
    Abstract: Compositions and methods related to anti-cancer terpenoid compounds isolated from plants in the Salviniaceae family, pharmaceutical compositions comprising the same, and methods of treating cancer.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: November 7, 2017
    Assignee: STEPHEN F. AUSTIN STATE UNIVERSITY
    Inventors: Shiyou Li, Ping Wang, Guangrui Deng, Wei Yuan, Zushang Su
  • Patent number: 9802962
    Abstract: Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to Alzheimer's Disease transgenic models resulted in substantially reduced soluble and insoluble A? species in the brain without affecting general behavior and motor coordination. Furthermore, in addition to blocking the toxicity and formation of both intraneuronal and extracellular A? aggregates, the compounds also increase cellular cholesterol efflux, restore axonal trafficking, and enhance hippocampal synaptic plasticity.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: October 31, 2017
    Assignees: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION, AFASCI, INC.
    Inventors: Duy H Hua, Lee-way Jin, Izumi Maezawa, Xinmin Xie
  • Patent number: 9707219
    Abstract: The present invention relates to a method of treating a glomerular disease with 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: July 18, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Dennis Sprecher, Robert Nicholas Willette
  • Patent number: 9693992
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: July 4, 2017
    Assignee: MannKind Corporation
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • Patent number: 9526720
    Abstract: The present invention relates to compounds that are useful for modulating hepatic cholesterol metabolism in an animal. The invention includes methods of making and using the compounds of the invention. The invention further provides methods of treating, preventing and/or alleviating a cholesterol related disorder, a cardiovascular disease and/or liver disease in an animal, such as a human, comprising administering compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, to the animal.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: December 27, 2016
    Assignee: The Broad Institute, Inc.
    Inventors: Marek Maria Nagiec, Jose R. Perez, Michelle Palmer, Adam Skepner, Eamon Comer
  • Patent number: 9468623
    Abstract: The present invention provides compound extracted from Garcinia species and the use of said compound in preventing and treating cancer.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: October 18, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Hong-xi Xu, Yuan-zhi Lao, Zhi-jie Ding, Hong Zhang, Kai-xian Chen, Hong-sheng Tan, Zhao-xiang Bian, Cheng-yuan Lin, Shi-lin Chen, Da-jian Yang, Ai-ping Lu, Albert Sun Chi Chan
  • Patent number: 9440987
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: September 13, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Asato Kina
  • Patent number: 9428494
    Abstract: The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. Compounds of the invention are useful to modulate (e.g. agonize or antagonize) opioid receptor function.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: August 30, 2016
    Assignee: University of Iowa Research Foundation
    Inventor: Thomas Prisinzano
  • Patent number: 9145422
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: September 29, 2015
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
  • Publication number: 20150148409
    Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 28, 2015
    Inventors: Guangdi WANG, Matthew E. BUROW, Stephen M. BOUE, Thomas E. WIESE, Quan JIANG
  • Publication number: 20150126573
    Abstract: The present invention relates to methods and compositions for the prevention or treatment of chronic obstructive pulmonary disease.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 7, 2015
    Inventors: Jorge Bernardo Boczkowski, Serge Adnot, Maylis Dagouassat, Jean-Marie Gagliolo
  • Publication number: 20150119406
    Abstract: Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to Alzheimer's Disease transgenic models resulted in substantially reduced soluble and insoluble A? species in the brain without affecting general behavior and motor coordination. Furthermore, in addition to blocking the toxicity and formation of both intraneuronal and extracellular A? aggregates, the compounds also increase cellular cholesterol efflux, restore axonal trafficking, and enhance hippocampal synaptic plasticity.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 30, 2015
    Inventors: Duy H. Hua, Lee-way Jin, Izumi Maezawa, Xinmin Xie
  • Publication number: 20150110735
    Abstract: A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction.
    Type: Application
    Filed: October 22, 2013
    Publication date: April 23, 2015
    Inventor: Steven Hoffman
  • Patent number: 9011905
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: April 21, 2015
    Assignee: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Patent number: 9011906
    Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: April 21, 2015
    Assignee: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Publication number: 20150099801
    Abstract: The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 9, 2015
    Inventors: Wesley Day, Barbara Troupin
  • Publication number: 20150093458
    Abstract: A nutritional supplement for increasing cognitive functioning. The supplement includes a flavonoid such as luteolin and a labdane diterpene such as forskolin. The supplement can also include one or any combination of L-phenylalanine, L-carnitine, acetyl-L-carnitine, and vitamin B6. Artichoke extract can be used as a source of luteolin. Methods of using the nutritional supplements to increase cognitive functioning are also included.
    Type: Application
    Filed: September 27, 2014
    Publication date: April 2, 2015
    Inventor: Justin SHER
  • Publication number: 20150087620
    Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 26, 2015
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
  • Publication number: 20150072953
    Abstract: The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of modulating joint inflammation, joint pain, joint stiffness, cartilage degradation, or improving mobility, range of motion, flexibility, joint physical function, or any combination thereof. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other joint management agents, such as non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, glucosamine compounds, neuropathic pain relief agents, or the like.
    Type: Application
    Filed: June 16, 2014
    Publication date: March 12, 2015
    Inventors: Lidia Alfaro Brownell, Min Chu, Mei-Feng Hong, Eu-Jin Hyun, Qi Jia, Ping Jiao, Hyun-Jin Kim, Mi-Ran Kim, Tae-Woo Kim, Bo-Su Lee, Young-Chul Lee, Breanna Moore, Jeong-Bum Nam, Mi-Sun Oh, Mi-Hye Park, Mesfin Yimam, Qian Zhang
  • Publication number: 20150072012
    Abstract: A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Ravichandran SRIPATHY, Venkata Narasimha Siva Rama Raju MANDAPATI, Gopaal AJAY, Nirvanashetty SOMASHEKARA, Ramchand Nanappan CHANIYILPARAMPU, Rama Raju GOKARAJU, Ganga Raju GOKARAJU, Kiran BHUPATHIRAJU, Dwarakanath ANJANA
  • Publication number: 20150065431
    Abstract: The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Nax/SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1?, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Inventors: Wei Xu, Seok Jong Hong, Robert D. Galiano, Thomas A. Mustoe
  • Patent number: 8969406
    Abstract: A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: in which A is p-quino, and R is selected from the group consisting of the following Formula 1a and Formula 1b, where n in Formula 1 is 1 or 2, m in Formula 1b is 1 or 2, and n? in Formula 1b is 1, 2, or 3:
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: March 3, 2015
    Assignee: China Medical University
    Inventors: Yang-Chang Wu, Kuo-Hsiung Lee, Fang-Rong Chang, Da-Wei Chuang, Juan-Cheng Yang
  • Patent number: 8969371
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: March 3, 2015
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Preston Klassen, Kristin Taylor
  • Publication number: 20150057343
    Abstract: The subject invention provides a method of treating acne in a subject which comprises topically and periodically applying to the subject's acne a composition comprising 3-phenyl-1-benzo[f]chromen-1-one and a pharmaceutically acceptable carrier, wherein the 3-phenyl-1-benzo[f]chromen-1-one is present in an amount effective to treat the subject's acne. The subject invention also provides a method of treating a skin condition associated with abnormal sebum secretion or abnormal sebaceous gland function in a subject, compositions in such methods and a sorting method for identifying agonists of AhR pathway, useful in such methods and compositions.
    Type: Application
    Filed: November 7, 2014
    Publication date: February 26, 2015
    Applicant: THESAN PHARMACEUTICALS, INC.
    Inventor: Jean Hilaire SAURAT
  • Publication number: 20150056166
    Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 26, 2015
    Inventors: Thomas Pietschmann, Sibylle Haid, Juliane Gentzsch, Christina Grethe, Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Mourad Elhabiri, Xavier Benlloch-Martin
  • Patent number: 8957057
    Abstract: The present invention concerns the uses of an azaphilone compound of formula (I): formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification for modulation of the activity of a nuclear hormone receptor and for prevention and/or treatment of a disease or disorder related to nuclear hormone receptor activity.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: February 17, 2015
    Assignee: Food Industry Research and Development Institute
    Inventors: Ta-Wei D. Liu, Yen-Lin Chen, Ming-Der Wu, Ming-Jen Cheng, Hui-Ping Chen, Wen-Jung Wu, Kai-Ping Chen, Yu-Shan Lin, Gwo-Fang Yuan
  • Patent number: 8957108
    Abstract: The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogs, and in particular, the flavone acetic acid analog, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise an antimicrobial therapeutic agent for the treatment of viral infections of DNA and RNA viruses in humans and non-human animals. The invention is especially suitable for use in a process of treating and preventing infection by, for example, rhinoviruses, enteroviruses, and influenza viruses.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: February 17, 2015
    Assignee: University of Maryland, Baltimore
    Inventors: Stefanie N. Vogel, Zachary J. Roberts, Jorge Blanco
  • Publication number: 20150044295
    Abstract: The present invention provides a combination product, which comprises immediate release pellet of phentermine and sustained-release pellet of topiramate, wherein the pellet of topiramate includes: a) a blank pellet core; b) an active drug layer that contains topiramate and is free of binding agent, the layer being located on surface of the blank pellet core; c) a sustained-release coating layer containing ethyl cellulose and PVP K30, the sustained-release coating layer being located on external of the active drug layer. The present invention further discloses a method for preparing the combination product.
    Type: Application
    Filed: March 20, 2013
    Publication date: February 12, 2015
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song LI, Chunseng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
  • Patent number: 8951561
    Abstract: The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: February 10, 2015
    Assignees: Duke University, Immunolight
    Inventors: Tuan Vo-Dinh, Frederic A. Bourke, Jr.
  • Publication number: 20150038569
    Abstract: Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Inventors: Hongxi XU, Hong ZHANG, Yuanzhi LAO, Xiaoyu WANG, Kaixian CHEN, Dajian YANG, Shilin CHEN, Chengyuan LIN, Zhaoxiang BIAN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150038568
    Abstract: A pharmaceutic composition for treating an allergic skin disorder. It has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the active component, which accounts for 5-35% by weight of the overall pharmaceutic composition.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 5, 2015
    Inventor: Liping Yang
  • Publication number: 20150030551
    Abstract: Provided are benzopyran compounds of formula I, for example, pomiferin-3?,4?-dimethyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. wherein R3, R4, R5, R6, R7 and R8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.
    Type: Application
    Filed: August 12, 2014
    Publication date: January 29, 2015
    Inventor: Seth J. ORLOW
  • Publication number: 20150024055
    Abstract: The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Padmanabh P. BHATT, Hua WANG
  • Patent number: 8933116
    Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: January 13, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Duane A. Burnett, William J. Greenlee
  • Publication number: 20150005373
    Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.
    Type: Application
    Filed: July 30, 2014
    Publication date: January 1, 2015
    Inventor: Jean Hilaire Saurat
  • Publication number: 20140377382
    Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 25, 2014
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Bettina Platt
  • Publication number: 20140350093
    Abstract: Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.
    Type: Application
    Filed: January 3, 2013
    Publication date: November 27, 2014
    Inventors: Leonard M. Neckers, Carole A.C. Sourbier, W. Marston Linehan, Jane B. Neckers, Min-Jung Lee, Bradley T. Scroggins, John A. Beutler
  • Publication number: 20140349918
    Abstract: The present invention relates to xanthone analogs. Such compounds may be used in the treatment of bacterial infections.
    Type: Application
    Filed: September 10, 2012
    Publication date: November 27, 2014
    Applicants: Singapore Health Services Pte Ltd., Agency for Science, Technology and Research
    Inventors: Hanxun Zou, Lakshminiarayan Rajanmani, Lei Zhou, Chang Chui Charles Tang, Jun Jie Koh, Tiang Hwee Donald Tan, Chandra Verma, Roger W. Beuerman, Shouping Liu, Saraswathi Padmanabhan
  • Publication number: 20140349919
    Abstract: The present invention relates to certain chromane-like cyclic prenylflavonoids, in particular the compounds of formulae (I), (II) and (III) as described and defined herein, for use in the treatment or prevention of a neurological disorder, as well as their use in promoting neuronal differentiation, neurite outgrowth and neuroprotection.
    Type: Application
    Filed: June 15, 2012
    Publication date: November 27, 2014
    Inventors: Ludwig Aigner, Eleni Oberbauer-Hofmann, Sébastien Couillard-Despres, Francisco Javier Rivera, Herbert Riepl, Corinna Urmann, Martin Biendl
  • Patent number: 8895057
    Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 25, 2014
    Assignee: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Patent number: 8895058
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 25, 2014
    Assignee: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Publication number: 20140341845
    Abstract: Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Applicant: lmmunolight, LLC.
    Inventor: Frederic A. BOURKE, JR.
  • Publication number: 20140322136
    Abstract: The present invention provides methods to reduce or inhibit weight gain by administering inhibitors of the SirT1 protein to a subject. Methods to identify such inhibitors are also disclosed.
    Type: Application
    Filed: May 6, 2014
    Publication date: October 30, 2014
    Inventors: Yansong GU, Hongzhe LI
  • Publication number: 20140314740
    Abstract: The invention provides compositions and methods for the prevention, amelioration, and/or treatment of diabetes complications, including ocular diseases associated with increased glucose transport and/or oxidative stress.
    Type: Application
    Filed: December 10, 2012
    Publication date: October 23, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Peter A. Campochiaro, Lili Lu